Spyre Therapeutics, Inc. SYRE Increase Decrease In Other Accounts Payable
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayable.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s increase decrease in other accounts payable.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s increase decrease in other accounts payable?
- Spyre Therapeutics, Inc. (SYRE) reported increase decrease in other accounts payable of $36K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s increase decrease in other accounts payable changed year-over-year?
- Spyre Therapeutics, Inc.'s increase decrease in other accounts payable decreased by 98.1% year-over-year, from $1.95M to $36K.